Navigation Links
First clinical trials successfully completed on potent new hepatitis C drug
Date:9/3/2010

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly improved.

Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries. The current treatment involves two drugs ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.

Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: "This is still a very early stage of the trials process but none the less a significant development. Successfully completing phase 1a demonstrates that the drug is safe, with no drug-related side effects at all in a single dose of 100mg.

"The efficiency of drug release in this study has also confirmed that one single dose a day is most likely enough in treating the virus.

"We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."

In 2008, laboratory tests showed INX-189 killed 90 per cent of the virus at very low (nanomolar) concentration, making it the most potent compound of its kind developed to date.

US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has announced it is looking forward to a second trial (phase 1b), which would evaluate the compound's effectiveness in Hepatitis C patients.

Cardiff University and Inhibitex filed a patent on INX-189 earlier this year. It has been cleared for human clinical trials by the Food and Drug Administration in the US.


'/>"/>

Contact: Lowri Jones
joneslc3@cardiff.ac.uk
Cardiff University
Source:Eurekalert

Related medicine news :

1. Almost 1 in 3 First-Time Deliveries Now Via C-Section
2. For the first time, researchers identify and isolate adult mammary stem cells in mice
3. Gold Standard/Elsevier first to launch state, federal controlled substance drug schedules
4. Southampton to conduct UKs first cochlear implant operation to give sound in both ears
5. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
6. K-State professors book is first to explore Two-Spirit literature in Northwest native groups
7. Deaf, hard-of-hearing students perform first test of sign language by cell phone
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
9. Doctors hard to find for patients in Massachusetts first for-profit health plan
10. Scientists develop the first model for investigating the origins of testicular cancer in humans
11. UCLA scientists for the first time identify a cell-of-origin for human prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... York, New York (PRWEB) , ... January 24, 2017 , ... ... for Brazilian butt lifts is on the rise. According to the American Society ... augmentations since 2000. On average, these procedures are performed every 30 minutes of every ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solution provider of enterprise software products, today announced a strategic partnership with ... Blue users to access and analyze their Fusion platform for building powerful enterprise ...
(Date:1/24/2017)... Calverton, MD (PRWEB) , ... January 24, 2017 , ... ... Year by MSC Cruises as part of the line’s 4th Annual MSC True ... Cruises’ top performing North American travel partners for the year based on overall business ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate Solutions, ... Series of webinars will start January 31 with a session about understanding healthcare ... health and benefits topics, including employee engagement, pricing transparency, population health and wellness, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Center for Hispanic ... leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at City ... as its Hispanic Leader of the Month. City of Hope is committed to stay ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 2017 Italy Ultrasound Systems Market Outlook to 2022 ... Summary ... 2022", provides key market data on the Italy Ultrasound Systems ... volume (in units) and average prices (USD) within market segements ... Systems and Hand Held Ultrasound (HHU) Systems. The report ...
(Date:1/24/2017)... -- Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced that ... results on Thursday, February 2, 2017, after the close ... a conference call at 10:00 a.m. ET on Friday, ... for the first quarter ended December 31, 2016.  A live ... at www.spanamerica.com under Investor Relations on the ...
(Date:1/24/2017)... , Jan. 24, 2017  BioSpecifics ... a biopharmaceutical company that originated and continues ... in class collagenase-based product collagenase clostridium histolyticum, ... the U.S. and Xiapex ®  in Europe, today ... a corporate overview at the upcoming NobleCon13 ...
Breaking Medicine Technology: